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ABSTRACT
2-5
demonstrated.
NASA technology has been suc
cessfully applied to applications in both clinical
medicine and in medical research. Results include
advances in medical research, improved clinical
diagnosis and treatment, and the introduction of
new or improved medical products.

The Biomedical Applications Team program spon
sored by the National Aeronautics and Space
Administration is an effective means for trans
ferring aerospace technology to applications in
medicine. A conceptual framework for medical
technology transfer is presented to describe the
transfer process in medicine and to supply a
rationale for the Biomedical Applications Team
methodology. Examples illustrate medical
technology transfer at the material, design,
and capacity levels. The roles of donor,
recipient, and transfer agent are illustrated
and factors essential to the success of medical
technology transfer are summarized.

At present, Biomedical'Applications Teams are
sponsored by NASA at the following institutions:
Research Triangle Institute
Post Office Box 12194
Research Triangle Park, NC 27709
Stanford University School of Medicine
701 Welch Road
Palo Alto, CA 94304

INTRODUCTION

University of Wisconsin
1500 Johnson Drive
Madison, Wisconsin 54706

Human cells, frozen, stored, and thawed without
damage, may be made available for therapeutic
use; people may benefit from the application of
stimulating and monitoring electrodes that
require replacement only once each week; and
clinical information systems are demonstrating
the potential for improved medical care without
increased costs. While none of these medical
advances are direct results of National Aero
nautics and Space Administration (NASA) research,
they have all benefitted from NASA technology.
The way NASA's Biomedical Applications Teams
stimulate such technology transfers not only
illustrate the value of second applications of
aerospace technology but can serve as a model
for successful technology transfer in other
areas.

PROGRAM OBJECTIVES AND APPROACH
The specific objective of the Biomedical Appli
cations Team program is to assist NASA in
obtaining widespread utilization of aerospace
technology in the medical field. Widespread
implies that a significant sector of the medical
community and the recipients of medical services
should be benefitted. Implicit in this program
objective is that utilization must be obtained
in a relatively rapid manner.
The largest potential for rapid and widespread
utilization of NASA technology in medicine is in
clinical medicine. Although advances in medical
research definitely have a beneficial impact on
the delivery of medical services, this is, in
general, a long term and expensive process. As
a result, benefits from the transfer of technology
to medical research are realized later than is the
case in clinical medicine.

The Space Act of 1958 required NASA to "provide
for the widest practical and appropriate dis
semination of information concerning its activity
and the results thereof." 1 The NASA Technology
Utilization Program was initiated in 1962 to
assist in satisfying this requirement.
In 1966, NASA established Biomedical Applications
Teams to stimulate and facilitate the transfer
of aerospace technology to applications in
medicine. These teams identified medical pro
blems, identified potentially applicable tech
nology, and took necessary and appropriate steps
to effect actual utilization of NASA technology
in medicine. In the intervening years, the
successful transfer of NASA technology to ap
plications in the medical field via the
Biomedical Applications Team program has been

Applications of technology in clinical medicine
usually involve the introduction of a new or
improved, commercially available, medical product.
Thus, the approach of the Biomedical Applications
Team at Research Triangle Institute (RTI) in
obtaining widespread utilization of NASA technology
is to direct its efforts primarily to solving
problems that involve the introduction of such
products.
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appropriately concerned only with solving a pro
blem. The manufacturer by necessity is concerned
with introducing a commercially viable product.
And, the donor frequently obtains only satis
faction as reward for involvement in the transfer
process. It is the task of the transfer agent to
bring the donor, recipient, and manufacturer
together in such a way that each views successful
technology transfer as the primary objective.
Completeness of the transfer effort must be a
major goal for all parties involved.

This emphasis on achieving widespread utilization
by commercializing NASA technology is reflected
in the methodology of the Biomedical Applications
Team program. The RTI team methodology is built
around the following four activities: (1) the
identification of medical problems and needs and
potentially applicable NASA technologies that
together constitute a new medical product op
portunity; (2) screening of opportunities to
identify those that represent potentially suc
cessful commercial products; (3) the develop-r
ment of commercialization strategies that take
into account any necessary adaptation of NASA
technology, evaluations and clinical trials,
PDA regulations, manufacturing, marketing
systems, and required funding; and, (4) imple
mentation and monitoring of commercialization
strategies.

The specific role of the transfer agent depends
upon the motivation, competence, and organization
of the donor, recipient, and manufacturer. NASA
is highly motivated to transfer aerospace
technology to applications in non-space-related
fields. Further, its organization is structured
to facilitate the development of sophisticated
and advanced technology. NASA's understanding
of the medical industry and clinical medicine, on
the other hand, is not extensive. The techno
logical competence of the recipient is highly
variable. Many medical researchers in large
medical centers and teaching hospitals are
technologically competent; the physician in
clinical practice, in general, will not be
technologically competent. The manufacturer of
medical products may have a long and successful
history of developing and marketing medical pro
ducts or may be a small agressive company ex
hibiting innovative behavior but lacking relevant
experience. It is the role of the Biomedical
Applications Team to recognize the strengths and
weaknesses of each participant and to supply the
motivation, competence, and institutional linkages
to ensure success.

The RTI Biomedical Applications Team is a multidisciplinary team of engineers and scientists.
Their educational backgrounds are physiology,
biophysics, engineering, biochemistry, and biomedical engineering; their experience includes
basic and applied research, development., and
marketing.
CONCEPTUAL FRAMEWORK
A conceptual framework for medical technology
transfer is presented diagrammatically in
Figure I. 6 The framework is basically a bipolar,
donor-recipient model for technology transfer.
The role of the donor, in this case NASA, is to
reveal, disseminate, and promote technology. The
role of the recipient, the medical community, is
to seek out, evaluate, and utilize technology.

Technology will be interpreted as including all of
the skills, techniques, and understanding as well
as the materials, devices, and hardware that make
up a specific technology.^ Technology transfer
as used throughout this paper will refer
specifically to "horizontal" technology transfer.
That is, the transfer of technology from one
situational context—the one for which the
technology was originally developed—to another
situational context. 9 This transfer will normally
result in either a modification of the technology
or a change in the situational context to which
it is transferred.

As explained in the Introduction, the primary
thrust of the Biomedical Applications Team pro
gram is to transfer technology by the intro
duction of new and improved medical products.
Thus, a manufacturer of those products is
included in Figure 1 . Medical technology trans
fer normally involves the identification of a
medical problem or need within the medical
community. In response, NASA recognizes the
relevance of specific aerospace technology and
makes that technology available. The manu
facturer designs, develops, evaluates, and
markets a new or improved medical product that
incorporates the aerospace technology and that
represents a solution to the medical problem or
need.

Ruttan and Hayami have defined three levels at
which technology transfer can occur. These levels
are: 10
Level 1; Material Technology Transfer. This
involves the transfer of hardware, unmodified,
from one situational context to another.
Level 2: Design Technology Transfer. In this
case, both hardware and software may be trans
ferred for the purpose of imitating the original
technology with some modifications for a new
application.
Level 3: Capacity Technology Transfer. This
level involves the transfer of knowledge and
ability so that the recipient can generate his
own technology.
In medical technology transfer, there are only a

The purpose of the transfer agent* is to plan,
stimulate, and facilitate such technology trans
fer. This is the role of the Biomedical
Applications Team.
Research into the process of medical technology
transfer at the Syracuse University Research
Center has concluded that the donor, recipient,
and manufacturer are frequently at cross
purposes.
The recipient is primarily and
*The terminology "linker" is frequently used
in this context.
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Biomedical Applications Team takes into account
these factors concerning innovative behavior of
the medical community in its problem identifi
cation activities.

few instances in which level 1, material, transfers
occur. The transfer of physiological electrodes
developed for use in space vehicles to use in
clinical medicine represents a level 1 transfer.
Most medical technology transfers are level 2
and level 3 transfers. The redesign of an aero
space component or system for application in
medicine constitutes a level 2 transfer. The
utilization of NASA-generated knowledge, tech
niques , and procedures in the development and
design of a new medical product constitutes a
level 3 transfer.

There are indications that medical technology
introduced in the past 10 to 20 years often has
tended to increase the sophistication of medical
diagnosis and treatment but has not contributed
to a reduction in the cost of health care nor to
increasing the quality of health care for the popu
lation as a whole.^ This indicates that there is
an opportunity for introducing aerospace technology
in a manner to reduce the cost of health care or
at least assist in containing health care costs.
The efforts of the Biomedical Applications Team
are directed to identifying opportunities that
potentially reduce or contain medical costs.

BIOMEDICAL APPLICATIONS TEAM METHODOLOGY

As noted in the Introduction and indicated in
Figure 2, the activities of the Biomedical
Applications Team can be separated into four
phases. Within each of these phases of the pro
gram, the specific actions and responsibilities
of the team are, to a certain extent, fixed.
However, team methodology incorporates flexi
bility that allows it to respond appropriately
to the specific characteristics of particular
technology transfer cases.

Technology relevant to medical problems and needs
is identified by a variety of techniques. Once a
medical problem or need is specified, a com
puterized information search of the aerospace
literature is performed by one of the six In
dustrial Applications Centers (lACs). The RTI
team utilizes the services of the IAC located in
Research Triangle Park, North Carolina—the North
Carolina Science and Technology Research Center.
These computerized information searches identify
information on potentially relevant technologies.

Identification of Opportunities
The identification of technology transfer op
portunities involves; (1) the identification of
a medical problem or need; and, (2) the identi
fication of relevant aerospace technology that
solves the medical problem or satisfies the
medical need.

An additional approach to identifying aerospace
technology is the circulation of Problem State
ments to NASA Field Centers. Individual medical
problems are concisely described in Problem
Statements. Each Problem Statement is sent to
NASA engineers and scientists working in areas
related to the medical problem. Responses to
Problem Statements from these engineers and
scientists can lead to the identification of
technological solutions.

The identification of medical problems occurs
through the direct interaction between a team
member and a researcher or physician within a
medical institution. At present, the RTI team
interacts directly with medical staff at 27
medical institutions throughout the eastern
United States.

Finally, the Biomedical Applications Team fre
quently contacts NASA scientists and engineers
known by the team to have a strong interest in
transferring technology to medicine. This is the
most direct, efficient, and rapid approach to
locating technology.

A study of medical technology transfer by the
National Academy of Engineering has concluded
that the recipient must take the lead in de
fining medical problems.H This is consistent
with the experience of the RTI team. As a result,
the Biomedical Applications Team emphasizes
obtaining complete and extensive descriptions of
medical problems and needs from medical re
searchers and clinicians.

A medical problem in combination with a poten
tially relevant aerospace technology constitutes
an opportunity for technology transfer. The next
phase of the program is the investigation of
factors that determine which opportunities are most
likely to be successful.

Certain medical institutions and medical pro
fessionals are more innovative than others.12
Research has shown that the first hospitals to
adopt innovations are generally large medical
centers or teaching hospitals geographically
close to the place where the technology was
developed. Further, those hospitals with highly
trained medical staff tend to be more innovative.
The "innovative elite" in medicine generally
act to improve the quality of health care rather
than to achieve maximum economic efficiency.
Finally, once a hospital has adopted an in
novation, the widespread use of that innovation
is enhanced if the innovating hospital interacts
frequently with other medical institutions. The

Screening
Effective screening of opportunities enables the
RTI Biomedical Applications Team to focus on those
opportunities with the most promise for successful
medical solutions and commercial products. In
order to continue work on a particular opportunity,
the team must determine that most of the following
requirements are satisfied:
• The solution improves medical treatment or
diagnosis or reduces the cost of health care;
• The solution is recognized by a medical mission
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agency and the medical community as a. contri
bution to improved health care;
• The solution incorporates NASA technology or
expertise;
• The market for the new or improved product
justifies the required capital investment andproduction cost to the manufacturer;
• A manufacturer can be offered protection
either by exclusive license or sudden entry of
the product into the medical market; and,,
• The solution represents a discrete* well 'de
fined transfer of technology Involving limited
research and development effort.
These factors are evaluated by reviewing the biomedical literature, market surveys* .interviews
with industry representatives* and discussions
with appropriate medical' staff.

Medical marketing and distribution frequently are
not an integral function of medical product manu
facturing firms. Thus, in addition to selecting
and obtaining the participation of a medical
product manufacturer, the team must also identify
and bring into the transfer process an organi
zation having the capability to market and dis
tribute those products.
Each specific opportunity for medical technology
transfer will offer a new set of barriers and
strategic options. Thus, the formation of a
strategy is not a repeatable and specific
activity. It is in itself a problem solving
effort. The most important common feature of
strategy formation is thoroughness. All con
tingencies must be anticipated.

Development of Strategies

Implementation and Monitoring

The development of strategy for successful tech
nology transfer must take into account product
development and marketing* clinical trials*
acceptance by the medical profession, and identi
fication of funding sources for the various tasks
involved ,

•Experience in the implementation of strategy has
shown that the chance for successful technology
transfer is increased by active involvement of
the Biomedical Applications Team throughout the
transfer process. By monitoring and coordinating
the activities of the participants, minor problems
can be prevented from becoming major obstacles.

The previously mentioned National Academy of
Engineering study of medical technology transfer
reached some Important conclusions concern,ing
strategy for tec hnology trams fer . *•*• Successful
technology transfer requires intimate and signifi
cant involvement of both the donor and recipient
throughout the transfer process* Further, the
involvement of industry throughout the transfer
process is essential. Finally* the manner in
which new technology is introduced to the medical
field is a critical factor in its success.

Reports and documentation are an integral part of
the team methodology; they are involved throughout
the technology transfer process. Implementation
of strategy is no exception; periodic status
reports are issued informally to keep all parti
cipants informed. Upon completion of the transfer
process, the team prepares a technology transfer
report documenting all important aspects of the
transfer process.

The experience of the RTI Biomedical Applications
Team has confirmed these conclusions and expanded
upon them. Industry must be involved throughout
the transfer process and must be brought into that
process as early as is possible., Further,, the
involvement of industry will generally require
some means for giving; a specific manufacturer a
proprietary position. This may involve either an
exclusive license or sudden entry of the new or
improved product into the medical market,, Indus
try will view new product opportunities from the
outside as being in competition with its own
internally generated product ideas. This means
that opportunities for technology transfer gener
ated through the Biomedical Applications Team
program will have to compete for industry
capital and management attention.

MEDICAL TECHNOLOGY TRANSFER EXAMPLES
Three examples of the transfer of aerospace
technology to applications in medicine are pre
sented to illustrate the transfer process. The
specific cases presented were selected: (1) to
illustrate material, design, and capacity trans
fers; (2) to elucidate the roles played by
donor, recipient, and transfer agent; and
(3) to emphasize other important aspects of
technology transfer in medicine. Further, each
case was selected such that the transfer process
was typical of medical technology transfer at the
material, design, and capacity levels.
Case 1:

The acceptance of a new product by the medical
community involves a fairly specific sequence
of events. Following development of the
product it must be subjected to clinical trials.
This must be followed by publication of the
results by a recognized medical expert.
Generally, the product must be exhibited at
medical meetings. This sequence of events
normally leads to physician acceptance.

Body Surface Electrodes
(Material Transfer)

Commercially available body surface electrodes
have been adequate for obtaining high quality EGG
signals for several years. These electrodes,
however, did not allow the long-term EGG moni
toring required in NASA's ground-based tests of
human subjects.
S, A. Rositano of NASA's Ames Research Center
developed a flexible electrode which allowed
continuous EGG monitoring for up to eight days
with excellent results. 5 ' 1
His first attempts
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involved suspending silver in a silicone rubber
matrix. This system exhibited long term de
gradation of the lead wire to elastomer contact.
A subsequent attempt involved the use of a silvercoated nylon net fabric similar to support
hosiery in texture and finish. This material
was both inexpensive and exhibited stable
resistivity. The flexible material permitted
construction of large electrodes that did not
restrict normal skin movement. Lead wires were
attached by riveting or conductive epoxy. Using
these electrodes with a gel-impregnated porous
paper, long term monitoring of subjects was
successful.

the amount of electrically generated thermal
energy injected at the tissue-liquid nitrogen in
terface can be adjusted rapidly to give precise
control of the tissue temperature. Two inno
vations are involved in this concept: (1) the
approach to control of cooling rate; and,
(2) precise temperature monitoring technology
developed by JPL for use in space.
Initial evaluations of the concept by NASA en
gineers, the Biomedical Applications Team, and
NCI were positive. Because it is located close
to NCI, NASA's Goddard Space Flight Center was
selected to design and fabricate a prototype
tissue freezing unit for evaluation at NCI.
Experiments in freezing and thawing human and
animal tissue at NCI indicated that the NASA
freezing unit could control freezing rates and
that stem cells and white cells could be frozen
and thawed with little cell damage.

The Stanford University Biomedical Applications
Team and Rositano recognized the potential value
of the NASA electrode to the medical field.
Rositano was invited to present a paper on the
NASA electrode at a conference at Stanford
University. Approximately 200 representatives
of NASA, industry, and the medical community had
been invited. As a result of that conference and
subsequent communications between a manufacturer
and NASA, the flexible long-term monitoring elec
trodes were made commercially available. The
manufacturer modified the material slightly to
minimize off-set potentials; otherwise, the
commercial electrodes were the same as the NASA
electrode.
Case 2:

Following validation of the freezing concept, JPL
engineers discussed the freezing unit, its suc
cess, and its potential applications with a number
of manufacturing firms. At present, JPL, with
significant funding from industry, is conducting
R & D to better understand the freezing process
and to generate data for designing freezing units
for specific applications.
Case 3:

Biological Tissue Freezing System
(Design Transfer)

Clinical Information System
(Capacity Transfer)

For a number of years, Duke University Medical
Center staff have been developing a clinical in
formation system with the objective of improved
medical care for patients with ischemic heart
disease. 1 JS —1*-'7 This medical information system
contains the medical histories of over 4,000 Duke
University Medical Center ischemic heart disease
patients. Information on disease state, medical
treatment, and patient response as well as in
formation on the patient's lifestyle are stored.
A physician at Duke University Medical Center can
obtain medical histories on a specific patient
profile that matches a patient presently being
treated. For example, the physician can obtain
medical treatments and patient responses for
patients in a particular age group, with certain
smoking habits, and with particular disease
symptoms. The system is proving to be a signifi
cant asset to the medical center staff.

The need to freeze, store, and subsequently thaw
healthy tissue without damage is an important
requirement. For example, transfusions of white
cells are frequently used in the treatment of
leukemia and a method of storing white cells is
needed. Commercially available tissue freezing
units damage a large fraction of the cells in
tissue.
Cell damage in the freezing process is thought to
result from a lack of precise control over the
rate of cooling. At the tissue freezing tempera
ture, the latent heat of the tissue is released
and the rate of cooling is drastically lowered.
The RTI Biomedical Applications Team discussed
this medical requirement in detail with an
engineer and medical researcher at the National
Cancer Institute (NCI) in 1970. A Problem State
ment concisely describing that requirement was
written and circulated to NASA Field Centers.
Engineers at NASA's Jet Propulsion Laboratory
(JPL) recommended an innovative technological
solution.

Early in the development of this information sys
tem, C. F. Starmer, Duke University Medical
Center, was attempting to develop a computer-based
system to identify and track the movement of nodes
in the coronary arterial trees recorded in biplane
cineangiograms. Discussions between Starmer and
the RTI Biomedical Applications Team identified
the image processing work at JPL as technology
relevant to Starmer's investigations. The RTI
team was able to assist Starmer in obtaining a
summer fellowship at the Jet Propulsion Laboratory
in 1970. As a result of his summer fellowship at
JPL and his continued communications with NASA
engineers, Starmer became knowledgeable of NASA
image processing technology which over a period

The concept proposed by JPL engineers is il
lustrated in Figure 3. This concept involves
placing the biological tissue in close proximity
to a sufficient quantity of liquid nitrogen to
freeze the material very rapidly. Electrical
resistance heating elements are placed between the
container of biological tissue and the liquid
nitrogen containers. By precisely monitoring the
temperature at the surface of the tissue container,
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of years was introduced into the medical center
clinical information system. Specifically, NASA
technology contributed to: (1) an easy-to-use
mechanism for inputting and storing graphic data;
and (2) a data storage system that facilitates
the use of accumulated patient data to develop
meaningful prognoses.

agent, the RTI Biomedical Applications Team, was
involved throughout the transfer process in com
municating the medical requirements to NASA, in
communicating potential solutions to NCI, in
coordinating the collaborative effort between
NASA and NCI, in avoiding potential barriers in
the transfer process, and in documenting the
process and the transfer. During the prototype
evaluation at NCI, the medical researcher who
had worked with the team in specifying the
medical requirement left NCI and the experimental
evaluation was temporarily terminated. Because
of the continued involvement of the RTI team and
the commitment to the project by other individuals
at NCI, the evaluation was continued after a
relatively short delay. It is judged that the
involvement of the donor, recipient, and transfer
agent were high throughout the transfer process,
and further, that this level of involvement was
critical to the success of the transfer process.

MEDICAL TRANSFER CASE ANALYSIS
Examples of material, design, and capacity tech
nology transfers in medicine have been presented.
Understanding of the technology transfer process
and of the participants' roles in that process
is enhanced by considering the relative involve
ment of the participants in these three examples
as summarized in Table 1.
TABLE 1
MEDICAL TECHNOLOGY TRANSFER CASE SUMMARY
Case Number
Level of Transfer

1
1

2
2

3

Transfer Agent Involvement

M

H

L

Donor Involvement

H

H

L

Recipient Involvement

L

H

H

Notes:

Case No. 3, clinical information system,is an
excellent example of a capacity transfer. The
involvement of the transfer agent, the RTI team,
was low. That involvement was assistance to
Starmer in obtaining a summer fellowship at JPL.
The involvement of the donor, NASA, was likewise
relatively low. On the other hand, the recipient
was intimately and extensively involved in NASA's
image processing technology and in applying that
technology in the clinical information system
over a period of years.

3

H—High level of involvement
M—Moderate level of involvement
L—Low level of involvement

The nature of material transfers as illustrated
by the body surface electrode case can be
characterized as a response by the donor to a
transfer opportunity. Identifying such op
portunities is highly dependent upon the presence
of individuals aware of both medical requirements
and technologies available in donor organizations.
Marketing is the major activity in material
transfers.

Transfers at the material level within the con
text of applying aerospace technology in the
medical field are infrequent. Even in the case
presented, body surface electrodes, the tech
nology was modified before becoming a commercial
product. The involvement of the recipient, the
medical community, was to confirm the medical
utility of the NASA electrode. On the other
hand, the involvement of the donor appears to
have been relatively high in that NASA was in
volved in developing the electrode and in trans
ferring required data and information to the
manufacturer. The involvement of the transfer
agent was to identify, in collaboration with the
donor organization, the potential for technology
transfer and to facilitate communications between
NASA, the medical community, and industry. This
is estimated to have been a moderate level of
involvement.

Design and capacity transfers are a long-term
process involving years of effort. Significant
commitments of resources by the donor, recipient,
or industry are required.
A high level of involvement on the parts of donor,
recipient, and transfer agent are critical to the
success of design technology transfers. In the
case of capacity transfers, the recipient bears
the burden of the effort.
In each of the three cases presented, the first
step in the transfer process was the identi
fication or confirmation of a medical requirement.
Thus, these transfers can be characterized by
"need-pull" as opposed to "technology-push."

The second example, the biological tissue
freezing system, is clearly a design transfer.
A significant development, design, and fabri
cation effort was required in building the pro
totype units. This effort was performed by NASA
and constitutes a high level of donor involve
ment. The recipient, NCI, identified the
requirement for the system, specified functional
characteristics of the freezing unit, acted as
consultant to Goddard Space Flight Center during
development and design of prototypes, and
evaluated the system through extensive experi
mental work. This certainly constitutes a high
level of recipient involvement. The transfer

In both design and capacity transfers,a transfer
agent is essential either within the donor
organization or having a strong association with
the donor organization. The NASA-sponsored
Biomedical Applications Teams appear to be ful
filling this role with increasing effectiveness.
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(5) Stanford University, Biomedical Technology
Transfer, Stanford University School of Medicine,
Palo Alto, California, September 1975.

CONCLUSIONS
NASA's Biomedical Applications Team program is
effectively transferring aerospace technology to
applications in medicine. These transfers are
occuring at the material, design, and capacity
levels with most of the activity occuring at the
latter two levels.

(6) Fischer, W.A., "Technology Transfer," June
1976 (in review).
(7) Teich, A., et al., Federal Laboratories and
Technology Transfer: Institutions, Linkages, and
Processes, Syracuse University Research Corpora
tion, Syracuse, New York 13210, March 1974.

NASA's Technology Utilization Program objectives
and the present state of health care delivery
have guided the Biomedical Applications Teams in
establishing program emphasis. That emphasis is
upon transferring technology via the introduction
of commercially available, medical products that
incorporate NASA technology. Further, emphasis
is upon applying technology to improve medical
diagnosis and treatment or to contain medical
costs.

(8) Kohler, B.M., et al., "A Behavioral Study of
International Technology Transfer Between the
United States and West Germany," Research Policy,
Vol. 2, 1973, pp. 160-184.
————————————
(9) Braahs, H., "National Science Policy and
Technology Transfer," in NSF 67-5, Technology
Transfer and Innovation, National Science
Foundation, 1967.

Successful technology transfer in medicine re
quires a continuing involvement of the donor,
recipient, and transfer agent in the transfer
process. Additionally, industry must be involved
early in the transfer process when a commercial
product is involved.

(10) Ruttan, V.W. and Y. Hayami, "Technology
Transfer and Agricultural Development," Technology
and Culture, Vol. 14, No. 2, Part I, 1973,
pp. 119-151.

Successful technology transfer is, in general, a
long-term process. The commitment of significant
resources is required by the donor, recipient,
or industry on a long-term basis.

(11) Committee on the Interplay of Engineering
with Biology and Medicine, National Academy of
Engineering, Study of Aerospace Technology
Utilization in the Civilian Medical Field, Final
Report to National Aeronautics and Space
Administration.

Continued study of horizontal technology transfer
in medicine and within the context of com
mercialization will result in greater program
productivity. Increased understanding of
government-industry linkages formed in technology
transfer is essential.

(12) Tannol, C.P. and E.M. Rogers, "Diffusion
Research Methodology: Focus on Health Care
Organizations," in G. Gordan and G. L. Fischer
(eds.), The Diffusion of Medical Technology,
Cambridge, Mass., Ballinger Publishing Co., 1975,
pp. 66-69.
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